MedTrace Logo

Personalized Needs in Clostridium Difficile Infections

NCT02573571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2017-10-05

No results posted yet for this study

Summary

To develop a score that can predict early from diagnosis of Clostridium difficile infection (CDI) the risk for relapse and of unfavorable outcome. This score can be used in the future to identify patients will benefit from fidaxomicin treatment.

Conditions

  • Biologic Markers
  • Clinical Markers

Interventions

OTHER

Development of biomarkers

Blood sampling

Sponsors & Collaborators

  • Hellenic Sepsis Study Group

    collaborator OTHER

  • University of Athens

    lead OTHER

Principal Investigators

  • Athanasios Skoutelis, MD · Evangelismos Athens General Hospital

  • Evangelos J Giamarellos-Bourboulis, MD, PhD · Attikon Hospital

  • George Chrysos, MD, PhD · Tzaneion Piraeus General Hospital

  • Styliani Symbardi, MD, PhD · Thriassio Elefsis General Hospital

  • Zoi Alexiou, MD, PhD · Thriassio Elefsis General Hospital

  • Kostantinos Syrigos, MD, PhD · Sotiria General Hospital

  • George Daikos, MD, PhD · Laikon Athens General Hospital

  • Panagiotis Gargalianos, MD, PhD · G.Gennimatas Athens General Hospital

  • Malvina Lada, MD, PhD · Sismanogleion General Hospital

  • Charalambos Gogos, MD, PhD · University Hospital of Patras

  • Ilias Athanasiadis, MD, PhD · Mitera General Hospital

  • Symeon Metallidis, MD, PhD · AHEPA Thessaloniki University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-12-31
Completion
2017-10-31

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02573571 on ClinicalTrials.gov